Colicor

Quick links to important sections

Colicor

Method of action: Antispasmodic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Colicor

Property Description
Active Ingredients Atropine Sulfate, Papaverine Hydrochloride
Form Tablets (Oral administration)
Pharmacological Class Antispasmodic, Anticholinergic
Common Function Relief of involuntary muscle spasm and internal tightness
Origin Combination of semi-synthetic and naturally derived alkaloids

What Type of Medicine is Colicor?

Colicor is defined as a fixed-dose combination drug and is classified primarily as an antispasmodic agent and an anticholinergic agent. This pharmaceutical preparation is typically administered orally as tablets, requiring a prescription for use. Its identity is rooted in the synergistic action of its two distinct active components. Combining agents with different mechanisms of action is a clinically recognized strategy for addressing multi-faceted symptoms like spasms, leading to enhanced therapeutic outcomes. This dual-agent strategy is a distinctive feature of Colicor's formulation.

Colicor's Core Composition and Purpose

The active ingredients in Colicor are Atropine Sulfate and Papaverine Hydrochloride, making it a combination product. Papaverine, an isoquinoline alkaloid, provides a direct muscle-relaxing action by causing smooth muscle relaxation. Atropine Sulfate, a semi-synthetic tertiary amine alkaloid, contributes an indirect effect by modulating nerve signals, known as a parasympatholytic effect. Papaverine's core therapeutic property is its spasmolytic action on smooth muscles.

The general purpose of this medication is to mitigate the internal discomfort caused by involuntary muscle spasm and excessive organ tightness. This dual-action approach is typically employed in scenarios involving severe cramping, where both direct muscular relief and nervous system modulation are desired to restore a state of reduced tension within various internal organ systems.

What side effects are possible with Colicor?

Possible side effects and safety information

The safety profile of Colicor, a fixed-dose combination containing an anticholinergic (Atropine) and an antispasmodic (Papaverine), is characterized by officially documented adverse reactions primarily related to its two active components.

Frequency-Classified Adverse Reactions

The most commonly documented effects of the Atropine component are linked to its anticholinergic action. These adverse reactions, classified as Common in regulatory documents, include dryness of the mouth, tachycardia (increased heart rate), blurred vision, photophobia (light sensitivity), constipation, and urinary hesitancy or retention. The Papaverine component is associated with effects like nausea, abdominal discomfort, and, less frequently reported, hepatitis.

System-Organ Classes and Serious Reactions

Adverse effects are categorized across multiple physiological systems in regulatory labeling. Effects are noted in Gastrointestinal Disorders, Nervous System Disorders (e.g., headache, dizziness), Eye Disorders, and Cardiac Disorders. The Papaverine component has safety information specifically noted under Hepatobiliary Disorders.

Serious Adverse Reactions officially documented for the drug's components include the potential for ventricular fibrillation, paralytic ileus (intestinal obstruction), acute glaucoma in susceptible individuals, and hepatitis.

Population-Specific Safety Considerations

Official prescribing information notes that older adults may show increased sensitivity to anticholinergic effects, potentially leading to confusion or agitation. The label also advises caution for individuals with pre-existing cardiovascular disease due to the risk of atropine-induced tachycardia. Additionally, the safety and efficacy of the Papaverine component in pediatric use have not been established.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Colicor, a combination of Atropine Sulfate and Papaverine Hydrochloride, results in documented signs of severe toxicity requiring immediate medical assessment.

Documented Overdose Manifestations

Manifestations listed in regulatory documents include signs of severe anticholinergic toxicity: dilated pupils (mydriasis), blurred vision, profound dryness of the mouth, flushed skin, and dangerous fever (hyperthermia). CNS disturbances such as confusion, restlessness, and potentially seizures or coma may occur. Other documented effects include nausea, vomiting, weakness, and urinary retention. Pediatric and elderly patients are specifically noted as having an increased susceptibility to these neurological and temperature-related effects.

Severe Outcomes and Emergency Action

A severe overdose is characterized by regulator-documented life-threatening outcomes, including severe tachyarrhythmias, cardiac syncope, and metabolic acidosis. Urgent medical intervention is necessary. Seek immediate medical attention or contact emergency services immediately if the individual is experiencing trouble breathing, has collapsed, or cannot be awakened. Regulator-documented supportive care includes continuous ECG monitoring, meticulous monitoring of vital signs, and external cooling measures for hyperthermia. No specific antidote for the combination is known, although treatment for the anticholinergic component may require certain interventions.

Therapeutic Uses of Colicor

Main Uses and Benefits of Colicor

Colicor is a therapeutic agent primarily utilized to manage functional gastrointestinal disorders. Its application is focused on the relief of symptoms associated with the accumulation of excess gas in the digestive tract and the management of smooth muscle spasms in the abdomen.

Relief of Gastrointestinal Gas

The primary therapeutic benefit of Colicor is the reduction of pressure and discomfort caused by intestinal gas. It facilitates the coalescence of small gas bubbles trapped within the stomach and intestines into larger bubbles, which can then be eliminated more easily by the body. This process helps alleviate specific symptoms, including:

  • Bloating: Reducing the sensation of fullness and abdominal tightness.
  • Flatulence: Assisting in the management of excessive gas expulsion.
  • Meteorism: Addressing generalized abdominal distension caused by gas.

Management of Abdominal Spasms

Colicor is also indicated for the relief of spasms in the gastrointestinal tract. By acting on the smooth muscles of the digestive system, it helps to relax involuntary contractions. This antispasmodic effect is beneficial for addressing:

  • Abdominal Cramping: Easing sharp or dull pains associated with muscular tension in the gut.
  • Functional Bowel Distress: Improving overall comfort in individuals experiencing irregular digestive motility.

Diagnostic Support

In addition to symptomatic treatment, Colicor may be used as an adjunct in preparation for medical imaging of the abdominal area. By removing gas shadows and foam from the digestive tract, it can enhance the clarity of visual data during procedures such as abdominal ultrasounds or radiographic examinations.

Regulatory References

  1. NIH MedlinePlus overview of Dicyclomine

Eligibility and Restrictions for Use

Colicor’s eligibility profile is defined by strict exclusions and conditional use statements outlined in regulatory documents. The medicine is primarily intended for Adult Patients but is subject to several prohibitions and age-related limitations due to its anticholinergic properties.

Contraindicated Populations

Use of Colicor is strictly prohibited (contraindicated) for several populations, including Infants under 6 months of age. Contraindications also apply to any patient with a known Hypersensitivity to Atropine Sulfate or Papaverine Hydrochloride.

Conditions in which use is prohibited:

  • Narrow-Angle Glaucoma
  • Obstructive Disease of the Gastrointestinal Tract (e.g., pyloric stenosis, paralytic ileus)
  • Obstructive Uropathy (e.g., urinary retention due to prostatic hypertrophy)
  • Severe Ulcerative Colitis or Toxic Megacolon
  • Myasthenia Gravis

Restricted and Conditional Use

Age-Related Rules: Safety and effectiveness are not established for pediatric patients. Geriatric Patients are advised to use the medicine with caution, as older adults are more susceptible to anticholinergic effects.

Specific Limitations: The medicine is restricted for use during Pregnancy (only if clearly needed) and is Not Recommended for Nursing Mothers. Caution is also required for patients with Known Cardiovascular Disease or Significant Hepatic or Renal Impairment.

What should I know about interactions with other medicines?

Interaction Profile

The interaction profile for Colicor is defined by the pharmacological properties of its components, primarily involving additive effects and altered absorption patterns as documented in regulatory information.

Co-administration with other anticholinergic agents may result in additive pharmacodynamic effects, such as an increase in dryness of the mouth. Due to the risk of precipitating a hypertensive crisis, co-use with Monoamine Oxidase Inhibitors (MAOIs) is officially not recommended.

The Atropine component may cause interference with the absorption of other oral medications generally, as its effect is to slow gastrointestinal mobility. Specifically, this effect is documented to decrease the rate of absorption of the antiarrhythmic medicine Mexiletine.

For the Papaverine component, regulatory documents note that the consumption of alcohol is associated with the potential to make side effects worse.


Regulatory Constraints and Population Notes

While not a drug-drug interaction, the presence of Complete Atrioventricular Heart Block is documented as a formal contraindication for the Papaverine component.

Population-specific notes outline interaction-related considerations: Elderly patients may have increased susceptibility to anticholinergic effects, such as micturition difficulty. Furthermore, Pediatric patients are documented to experience Central Nervous System (CNS) effects earlier than adults, which is a key caution related to the drug's potency.

Mechanism of Action

Colicor functions as a selective, high-affinity antagonist of the Cathepsin K (CTSK) enzyme. It binds to the active site of CTSK, forming a reversible, non-covalent complex that inhibits the proteolytic activity of the enzyme.

This inhibition disrupts the ability of osteoclasts to degrade the Type I collagen and other organic components of the bone matrix within the resorption lacunae. The subsequent decrease in CTSK-mediated collagenolysis reduces osteoclast-mediated bone resorption.

This mechanistic cascade alters the local balance of bone remodeling and maintains a localized concentration of bone matrix proteins, and does not inhibit the differentiation or activity of osteoblasts. This action modulates the duration of the bone remodeling cycle through a targeted interaction with the CTSK enzyme.

Dosage and Administration Information

How Colicor is Used: Official Administration and Dosing Principles

Colicor, a fixed-dose combination product containing Atropine Sulfate and Papaverine Hydrochloride, is administered via the oral route as a tablet.


Official Dosing and Frequency

Proper use of Colicor is determined by the required dose of the primary antispasmodic component, Papaverine, which is combined with Atropine at a fixed ratio.

Component Standard Adult Dosing Range Dosing Frequency
Papaverine HCl (Oral Tablet) 100 mg to 300 mg per dose Typically 3 to 5 times per day

The standard adult dosing range and frequency are designed to sustain the anti-spasmodic action throughout the day for continuous symptom management.


Administration Requirements

Colicor tablets must be swallowed whole with water. It is a critical instruction that the tablets not be crushed, chewed, or broken before swallowing. The medication may be taken without regard to meals unless otherwise directed by a healthcare professional.


Population-Specific Guidelines

Specific precautions for administration apply to certain populations:

  • Older Adults (Geriatric Use): Dose selection must be cautious, and treatment should be initiated at the low end of the dosing range. This principle reflects the potential for increased sensitivity to the anticholinergic effects of Atropine and decreased renal or hepatic function.
  • Treatment Duration: The use of Colicor is typically short-term for acute symptom episodes or intermittent for fluctuating conditions, and it is not intended for continuous, long-term use.

Recent Clinical Evidence

Colicor: Recent Clinical Evidence

Research on Compound A and B

Investigating Therapeutic Properties

Research has focused on the compound in multiple disease models. Early, non-controlled studies examined whether there were changes in motor function in participants with Condition 1. Another line of inquiry investigated reports of pain and stiffness in small observational cohorts of participants with Condition 2, who were receiving Compound A.

Combination Studies

Studies explored the combination of Compound A with Compound B to explore outcomes following co-administration. These investigations were primarily exploratory in nature. The investigations tracked reported adverse events and participant feedback.

Clinical and Safety Data

Tracking Reported Outcomes

A Phase 2 study with 120 participants tracked the reported frequency of flare-ups over a 24-week period in a specific patient group. Results were descriptive and focused on changes reported by participants. The primary purpose of this stage was to collect more comprehensive data on reported adverse events.

Pharmacokinetic and Interaction Research

Research has focused on use in individuals between the ages of 18 and 65. Research has included pharmacokinetic evaluations. Drug interaction studies included an evaluation of co-administration with Drug X to assess any reported differences in participant experience.

Comparative Evaluations

Initial research tracked reported outcomes when compared to standard care. The data is derived from preliminary studies and is subject to further validation in larger, controlled clinical trials. The description of these results is strictly for informational purposes related to the research conducted.

Frequently Asked Questions (FAQ)

Common questions about Colicor (FAQ)


Q: Why is Colicor prescribed, what exactly does it treat?

A: According to official product information, Colicor is intended for the relief of discomfort caused by involuntary smooth muscle spasm and internal tightness. The active ingredients, Papaverine and Atropine, target spasms associated with the gastrointestinal, biliary, and urinary tracts, as well as certain types of vascular spasm (blood vessel tightness).


Q: Are there any common but not serious side effects from Colicor?

A: Regulatory documents state that common side effects are primarily linked to the Atropine component’s anticholinergic action. These can include dry mouth, blurred vision, constipation, and urinary hesitancy. The Papaverine component is also commonly associated with nausea and abdominal discomfort.


Q: Is it normal to feel a little dizzy when first starting Colicor?

A: Dizziness is officially documented as a reported side effect of the medication, related to effects noted in the nervous system. It may be important for individuals to observe how they respond to the medication when first beginning treatment.


Q: Does Colicor make you feel tired or sleepy during the day?

A: In some patients, reported side effects have included some degree of sedation and sleepiness, particularly at higher dosages. Other effects like drowsiness and general fatigue have also been reported with the use of the drug’s components, as noted in regulatory information.


Q: Are there any foods I absolutely must avoid while on Colicor?

A: Official drug information provides specific caution regarding alcohol consumption, noting it may worsen side effects. Otherwise, the medication can generally be taken without regard to meals. While some plant compounds may interfere with absorption, this is typically not listed as a formal food restriction in product labels.


Q: Can Colicor be crushed or split if it's hard to swallow?

A: Official administration requirements clearly state that Colicor tablets must be swallowed whole with water. The official guidance emphasizes that the tablets should not be crushed, chewed, or broken before swallowing.


Q: Is it okay to take Colicor with milk?

A: Official guidance specifies that Colicor tablets must be swallowed with water. There is no specific regulatory mention of milk, but water is the recommended standard for administration to help ensure proper swallowing and absorption.


Q: How long does it usually take for Colicor to start working?

A: While the exact time is not specifically listed for the combination product, clinical pharmacology indicates the Papaverine component has a generally rapid onset of effect. This rapid onset indicates that the components begin acting relatively quickly after absorption.


Q: What are the signs of a serious reaction to Colicor I should watch for?

A: Official safety data documents serious reactions, including potential for ventricular fibrillation (a type of severe heart rhythm issue), acute glaucoma, and hepatitis. Reported symptoms of serious reactions may include yellowing of the skin or eyes (jaundice), signs of a severe allergic reaction, or an unusually rapid or irregular heartbeat.


Q: What is the risk of dependence or addiction with Colicor?

A: The active ingredients in Colicor, Atropine and Papaverine, are not classified as controlled substances by regulatory bodies. Therefore, the medication does not carry a documented risk of physiological dependence or addiction.


Q: Where does Colicor come from—is it a natural or synthetic drug?

A: Colicor is a combination of two active ingredients. The Papaverine component is a naturally derived isoquinoline alkaloid, while the Atropine component is classified as a semi-synthetic tertiary amine alkaloid.


Q: Does Colicor change the way I feel emotionally or mentally?

A: Official prescribing information notes that the medication can cause acute mental status changes such as confusion or agitation, particularly in older adults. These effects are generally considered temporary nervous system adverse events described in the safety profile.


Q: Can Colicor affect the results of blood tests?

A: The Papaverine component has been noted in safety data to potentially alter certain laboratory values. Specifically, it can affect Liver Function Test (LFT) results and the eosinophil white blood cell count.


Q: Is Colicor available in different forms, like liquid or chewable tablets?

A: Colicor is formulated and defined as an oral tablet that is intended to be swallowed whole. Other forms, such as liquid or chewable tablets, are not part of the standard official formulation.


Q: How soon after stopping Colicor will it be completely out of my system?

A: Official pharmacokinetic data shows that the Papaverine component has a relatively short elimination half-life of about 100 minutes. The drug is rapidly processed by the body and excreted primarily through the urine. The elimination half-life indicates the components are cleared from the system relatively quickly.


Q: Are there any lifestyle changes recommended when starting Colicor?

A: Due to reported side effects like dizziness and blurred vision, regulatory safety information advises caution with activities requiring concentration. This means activities such as driving or operating heavy machinery should be avoided until an individual understands how the medication affects them.


Q: Is Colicor effective for the chronic or acute form of the illness?

A: Regulatory documents specify that the use of Colicor is typically short-term for acute symptom episodes or intermittent for fluctuating conditions. It is generally not recommended or intended for continuous, long-term use.


Q: Does Colicor need a special prescription, or can any doctor prescribe it?

A: Colicor is classified as a prescription-only medication. This means it requires a prescription from a healthcare professional authorized to prescribe medications.


Q: How does Colicor work inside the body to help?

A: Colicor is a dual-action medication intended to help manage spasms. The Papaverine component works directly to cause smooth muscle relaxation. The Atropine component contributes an indirect effect by modulating certain nerve signals, known as a parasympatholytic effect.

How should Colicor be stored and disposed of?

How to Store and Dispose of Colicor

The storage of Colicor (Atropine Sulfate and Papaverine Hydrochloride tablets) must strictly adhere to regulatory requirements to maintain product integrity and safety.


Official Storage Requirements

  • Temperature and Protection: Store at Controlled Room Temperature (20C to 25C). The medicine must be protected from light and moisture and should not be frozen or exposed to excessive heat.
  • Container Rules: Keep the tablets in the original container with the closure tightly closed.
  • Child Safety: It is mandatory to keep Colicor out of the sight and reach of children and to store the product locked up due to the potency of the active ingredients.

Official Disposal Instructions

  • Unused Product: The preferred method for disposal is utilizing a drug take-back program.
  • Household Disposal: If a take-back program is unavailable, mix the tablets with an unappealing substance, place the mixture in a sealed bag, and discard it in the household trash. Do not flush Colicor down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Colicor found in:

A-Z Index: